1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(MARK ONE)
(X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934.
For the quarterly period ended March 31, 2001.
--------------
OR
( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934.
For the transition period from to
---------------- -------------
Commission File number 0-935
-----
AMPERSAND MEDICAL CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 36-4296006
- ---------------------------------- --------------------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
414 North Orleans Street, Suite 510
Chicago, IL 60610
----------------------------------------
(Address of principal executive offices)
(Zip Code)
(312) 222-9550
-------------------------------
(Registrant's telephone number, including area code)
-------------------------------------------
(Former name, former address and former fiscal year,
if changed since last report)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter periods that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes X No
--- ---
APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
PROCEEDINGS DURING THE PRECEDING FIVE YEARS
Indicate by check mark whether the registrant has filed all documents and
reports required to be filed by Sections 12, 13, or 15(d) of the Securities
Exchange Act of 1934 subsequent to the distribution of securities under a plan
confirmed by the court. Yes No
---- ----
APPLICABLE ONLY TO CORPORATE ISSUERS
Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practical date.
Common Stock, $0.001 par value per share----30,211,457 shares as of April 30,
2001.
1
2
INDEX
AMPERSAND MEDICAL CORPORATION AND SUBSIDIARIES
Part I. Financial Information
Item 1. Financial Statements (Unaudited)
Consolidated balance sheets -- March 31, 2001 and December 31,
2000
Consolidated statements of operations -- Three months ended
March 31, 2001 and March 31, 2000
Consolidated statements of cash flows -- Three months ended
March 31, 2001 and March 31, 2000
Notes to consolidated financial statements -- March 31, 2001
Item 2. Management's Discussion and Analysis of Financial Condition
and Results of Operations
Item 3. Quantitative and Qualitative Disclosure of Market Risk
Part II. Other Information
Item 1. Legal Proceedings
Item 2. Changes in Securities and Use of Proceeds
Item 3. Defaults on Senior Securities
Item 4. Submission of Matters to a Vote of Security Holders
Item 5. Other Information
Item 6. Exhibits and Reports on Form 8-K
2
3
PART 1. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
AMPERSAND MEDICAL CORPORATION AND SUBSIDIARIES
(FORMERLY BELL NATIONAL CORPORATION)
CONSOLIDATED BALANCE SHEETS
(DOLLARS IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
BALANCE BALANCE
MARCH 31, 2001 DECEMBER 31, 2000
-------------- -----------------
(UNAUDITED)
-----------
ASSETS
Current Assets:
Cash and cash equivalents $ 931 $ 13
Notes receivable, 1,250 330
Accounts receivable, net of allowance for doubtful
accounts of $4 344 465
Accrued interest receivable 101 73
Work in progress 212 248
Refundable taxes 115 119
Prepaid expenses 82 151
----------- ---------------
Total current assets 3,035 1,399
Fixed assets, net 519 385
Other assets:
License, patents, and technology, net of amortization 1,620 1,637
Goodwill, net of amortization 104 148
Prepaid royalties 990 1,006
----------- ---------------
Total assets $ 6,268 $ 4,575
=========== ===============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 1,548 $ 1,909
Deposits 24 547
Accrued payroll costs 90 231
Accrued expenses 516 586
Deferred revenue 67 195
Revolving line of credit 78 127
Current maturities of notes payable - related party 440 709
Current maturities of notes payable 427 396
----------- ---------------
Total current liabilities 3,190 4,700
Stockholders' equity (deficit)
Preferred Stock; Authorized 5,000,000 shares
Series B Convertible; issued
and outstanding 1,333,856 shares 1 -
Common stock, $0.001 par value;
Authorized 50,000,000 shares;
Issued and outstanding; 30,211,457 shares 30 30
Additional paid in capital 17,980 12,018
Note receivable from stockholder (450) (450)
Accumulated deficit (14,399) (11,626)
Accumulated comprehensive loss -
Cumulative translation adjustment (84) (97)
----------- ---------------
Total stockholders' deficit 3,078 (125)
----------- ---------------
Total liabilities and stockholders' deficit $ 6,268 $ 4,575
=========== ===============
The accompanying notes are an integral part of these consolidated financial
statements
3
4
AMPERSAND MEDICAL CORPORATION
(FORMERLY BELL NATIONAL CORPORATION)
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
(DOLLARS IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
THREE MONTHS ENDED
MARCH 31,
--------
2001 2000
----------- -----------
Net Sales $ 409 $ 362
Cost and Expenses
Cost of goods sold 278 190
Research and development 883 806
Selling, general, and administrative
expenses 1,754 2,483
----------- -----------
2,915 3,479
----------- -----------
Operating loss (2,506) (3,117)
Other income (expense)
Interest (expense) - related party (176) (1)
Interest (expense) (51) (20)
Interest income, related party 9 -
Interest income 18 -
Other, net 3 (1)
----------- -----------
(197) (22)
----------- -----------
Loss before income taxes (2,703) (3,139)
Income taxes - -
----------- -----------
Net loss $ (2,703) $ (3,139)
Preferred stock dividend $ (70) $ -
----------- -----------
Net loss available to common stockholders $ (2,773) $ (3,139)
Basic and fully diluted net loss per
common share $ (0.09) $ (0.15)
=========== ===========
Weighted average number of
common shares outstanding 30,211,457 21,300,522
=========== ===========
The accompanying notes are an integral part of these consolidated financial
statements.
4
5
AMPERSAND MEDICAL CORPORATION
(FORMERLY BELL NATIONAL CORPORATION)
CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
(DOLLARS IN THOUSANDS)
THREE MONTHS ENDED
MARCH 31,
--------
2001 2000
------- -------
Operating Activities:
Net loss $(2,703) $(3,139)
Adjustments to reconcile net loss to net cash used in
operating activities:
Amortization of debt discount 180 -
Depreciation and amortization 122 88
Stock, warrants, and options issued to non-employees for services 345 342
Compensation expense related to Stock Appreciation Rights 232 1,519
Expenses paid with common stock 22 -
Changes in assets and liabilities:
Receivables, net 93 73
Work in progress 36 (101)
Refundable taxes 4 -
Prepaid royalties 16 -
Prepaids and other assets 69 (73)
Accounts payable (361) (280)
Deposits (23) 7
Deferred revenue (128) 22
Accrued royalties - 250
Accrued expenses (211) (189)
------- -------
Net cash used in operating activities (2,307) (1,481)
Cash used in investing activities:
Payments for acquisitions - -
Expenditures for license, patents and technology (25) (12)
Purchase of fixed assets (170) (65)
------- -------
Net cash used in investing activities (195) (77)
Cash flows from financing activities:
Proceeds from issuance of notes payable, related party 495 -
Payment of notes payable - -
Payment of notes payable - related party (795) (26)
Advances for notes receivable (920) -
Proceeds from revolving line of credit, net of payments (49) (86)
Proceeds from issuance of preferred stock stock, net of costs incurred 5,176 -
Proceeds from issuance of common stock, net of costs incurred - 1,855
Application of deposit received for purchase of preferred stock (500)
------- -------
Net cash provided by financing activities 3,407 1,743
------- -------
Effect of exchange rate changes on cash 13 (10)
------- -------
Net increase (decrease) in cash and cash equivalents 918 175
Cash and cash equivalents at beginning of period 13 36
------- -------
Cash and cash equivalents at end of period $ 931 $ 211
======= =======
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during the period for:
Interest $ 2 $ 2
Income taxes $ -
Non-cash transaction during the period for:
Deferred financing costs $ 118 $ -
The accompanying notes are an integral part of these consolidated financial
statements.
5
6
AMPERSAND MEDICAL CORPORATION AND SUBSIDIARIES
Notes to Consolidated Financial Statements
(Unaudited March 31, 2001)
NOTE A. BASIS OF PRESENTATION
The accompanying unaudited consolidated financial statements have been
prepared in accordance with generally accepted accounting principles for interim
financial information and with instructions to Form 10-Q and Article 10 of
Regulation S-X. Accordingly, they do not include all of the information and
footnotes required by generally accepted accounting principles for complete
financial statements. In the opinion of management, all adjustments (consisting
of normal recurring accruals) considered necessary for a fair presentation have
been included. Operating results for the three-month period ended March 31, 2001
are not necessarily indicative of the results that may be expected for the year
ended December 31, 2001.
The balance sheet at December 31, 2000 has been derived from the
audited financial statements at that date but does not include all of the
information and footnotes required by generally accepted accounting principles
for complete financial statements.
For further information, refer to the consolidated financial statements
and footnotes thereto included in the Ampersand Medical Corporation and
Subsidiaries' Annual Report on Form 10-K for the year ended December 31, 2000.
NOTE B. OVERVIEW
Ampersand Medical Corporation, which may also be referred to as
("Ampersand"), was incorporated in Delaware on December 15, 1998, as the
successor to Bell National Corporation ("Bell National"). Bell National was
incorporated in California in 1958.
On December 4, 1998, Bell National (then a shell corporation without
any business activity) acquired InPath, LLC, a development-stage company engaged
in the design and development of medical instruments and related tests. In the
acquisition, Bell National issued 4,288,790 shares of Common Stock and warrants
to purchase 3,175,850 shares of Common Stock to the members of InPath in
exchange for their units of membership interest in InPath and the senior
executives of InPath assumed management control of the Company.
Based upon the terms of the acquisition agreement, for financial
reporting and accounting purposes the acquisition has been accounted for as a
reverse acquisition whereby InPath is deemed to have acquired Bell National.
However, Bell National was the continuing legal entity and registrant for both
Securities and Exchange Commission filing purposes, and income tax filing
purposes, until its merger into Ampersand in May 1999. Because Bell National was
a non-operating public shell company with nominal assets and InPath was a
private operating company, the acquisition has been recorded as the issuance of
stock for the net monetary assets of Bell National, accompanied by a
recapitalization and no goodwill or other intangible assets were recorded.
The Company is focused on the design, development and marketing of the
InPath System of products. These products are intended to detect cancer and
cancer related diseases. These products may be used in a laboratory, clinic, or
doctor's office.
The Company has a wholly owned subsidiary, Samba Technologies, Sarl
("Samba"). The Company acquired all of the assets of Samba in January 1999 from
Unilog Regions, SA, for approximately $500,000 in cash. Samba designs, develops,
and markets web-enabled software based systems for image analysis, image
capture, and image transmission and management for clinical and industrial
applications. Samba is also developing software used in the Inpath System. All
revenues since inception of the Company have been generated by Samba.
6
7
The Company has incurred a significant operating loss since its
inception. The Company expects that significant on-going operating expenditures
will be necessary to successfully implement its business plan and develop,
manufacture and market its products. These circumstances raise substantial doubt
about the Company's ability to continue as a going concern. Implementation of
the Company's plans and its ability to continue as a going concern may depend
upon it acquiring substantial additional financing. Management's plans include
efforts to obtain additional capital. In February 2001, the Company raised
approximately $5,176,000, including $500,000 received as a deposit in December
2000, from the private sale of 1,333,856 shares of its Series B Convertible
Preferred Stock to finance its operations (See Note D). However, there can be no
assurance that the Company will continue to be successful in raising capital
should the need for such capital arise in the future. If the Company is unable
to obtain additional capital, or generate profitable sales revenues, the Company
may be required to curtail the its product development and other activities and
may be forced to cease operations.
NOTE C. NOTES RECEIVABLE
On February 7, 2001, the Company and AccuMed signed a definitive
agreement under which AccuMed would be merged into a wholly owned subsidiary of
the company. Such agreement was amended on May 10, 2001 (See Note H). In
connection with the merger agreement, Ampersand loaned AccuMed $800,000 (which
includes $330,000 of prior loans) when the merger agreement was signed. Under
terms of the merger agreement, Ampersand loaned AccuMed $225,000 on March 1,
2001 and March 30, 2001 and $150,000 on May 1, 2001. Ampersand will continue
making monthly loans to AccuMed, beginning with a June 1, 2001 loan, in amounts
of $100,000. AccuMed may request additional loan amounts each month, above the
$100,000 level, to a maximum of $225,000, based on a written submission to
Ampersand substantiating the business need for the additional loan amount. All
such loans accrue interest at an annual rate equal to the Prime Rate announced
by the LaSalle National Bank, plus 2.5%. All principal and interest due under
all such loans shall be due and payable on the earlier of the termination of the
merger agreement or July 31, 2001, unless such date is automatically extended to
September 30, 2001, in accordance with the terms of the agreement. All such
loans are secured by the grant of a security interest and lien against the
collateral described in a security agreement between the parties.
NOTE D. DEPOSITS
On December 17, 2000, the Company received $500,000 from Monsun, AS, a
potential investor in a private offering of equity securities of the Company.
The funds were subject to return until such time as the final terms and
conditions of the offering were finalized. In February 2001, Monsun, AS signed a
subscription agreement to purchase 125,000 shares of the Company's Series B
Convertible Preferred Stock. The deposit was applied to the purchase price of
such stock (See Note F).
NOTE E. NOTES PAYABLE RELATED PARTIES
On February 1, 2001 and February 7, 2001, the Company issued
Promissory Notes to Azimuth Corporation ("Azimuth") in exchange for $25,000 and
$470,000, respectively, in cash. Those notes bore interest at the rate of 15%
per annum. Those notes were required to be repaid from the proceeds of any new
offering of debt or equity undertaken by the Company subsequent to the dates of
the Notes. As additional consideration for the Note issued on February 7, 2001,
the Company granted Azimuth a warrant to purchase 1,000,000 shares of Common
Stock of the Company at an exercise price of $0.25 per share, an approximate
83% discount from the market price of the Common Stock on the date the warrant
was issued. That warrant expires five years from the date of the grant. The
Company determined the value of the warrant to be $118,000 and charged the
entire amount to interest expense during the quarter. The Company repaid both
Notes and accrued interest on February 20, 2001. The Company also repaid two
additional promissory notes, issued in December 2000, and accrued interest on
February 20, 2001. The proceeds of the February 2001 Notes were used to fund a
portion of the loan to AccuMed upon the signing of the agreement on February 7,
2001, pursuant to which AccuMed will merge into a subsidiary of the Company.
NOTE F. STOCKHOLDERS EQUITY
SALE OF EQUITY
In October 2000, the Board of Directors authorized the Company to raise
additional new equity to support current and future operations. In February
2001, the Company completed the private offering of 1,333,856 shares of its
Series B Convertible Preferred Stock. The Series B Convertible Preferred Stock
has a par value of $0.001 per share, a stated value of $4.00 per share, a
cumulative dividend rate of 10% per annum, and is convertible into Common Stock
at a conversion price equal to $1.00 per share. The Company received net cash
proceeds from the February 2001 offering of $5,176,000, including $500,000
received in December 2000, as further described in Note D. Several advisory
groups contracted to assist the Company in finding
7
8
investors for the offering, were compensated through the payment of $159,000 in
cash, the issuance of 374,000 shares of Common Stock, and the issuance of
warrants to purchase 534,000 shares of common Stock at an exercise price of
$1.20 per share.
ISSUANCE OF RESTRICTED SHARES FOR SERVICES
Beginning in 1999, the Company has, at various times, awarded
restricted shares of Common Stock to non-employee consultants for services. Some
of the share awards were made for past services and their value was fixed. Other
share awards were made as partial consideration for services to be performed
under three-year consulting agreements and vest over the life of the agreements.
The measurement date of these shares had not been determined as of March 31,
2001 and therefore the value of these shares will be based on the market value
of the Common Stock at the end of each interim period until the measurement date
is determined. A fair value of these shares of $233,000 was calculated at March
31, 2001 using the Black-Scholes valuation model and the Company recorded
$38,000 as expense during the quarter.
ISSUANCE OF STOCK OPTIONS TO NON-EMPLOYEES FOR SERVICES
Beginning in 1999, the Company has, at various times, granted options
to purchase shares of Common Stock to non-employee consultants. The options were
issued as partial consideration for services to be performed under three-year
consulting agreements and vest over the life of the agreements. The measurement
date of these options has not been determined as of March 31, 2001. A fair value
of $607,000 was calculated for these options at March 31, 2001, using the
Black-Scholes valuation model. This value is charged to expense over the term of
the consulting agreements. The amount of expense to be ultimately recognized
will vary depending on the market value of the Common Stock at the end of each
interim period. The Company recorded $106,000 as expense related to these
options during the quarter.
ISSUANCE OF WARRANTS FOR SERVICES
In November 2000, the Company issued warrants to purchase 200,000
shares of Common Stock, at a price of $1.00 per share. In January 2001, the
Company issued additional warrants to purchase 100,000 shares of Common Stock at
$1.50 per share and 80,000 shares of Common Stock at $2.50 per share. All of
these warrants were issued to non-employees as compensation for financial
services to be provided under agreements covering a one-year period. The
warrants vest in equal amounts each month over the period. The Company may
terminate the agreements upon thirty days written notice, and any unvested
warrants as of the date of termination would be cancelled. The measurement date
for these warrants has not been determined as of March 31, 2001. A fair value of
$459,000 was calculated for these warrants at March 31, 2001, using the
Black-Scholes valuation model. The amount of expense to be ultimately recognized
will vary depending on the market value of the Common Stock at the end of each
period. The Company recorded $200,000 as expense related to these warrants
during the quarter.
In applying the Black-Scholes valuation model, the Company used an
expected dividend yield of zero, a risk-free interest rate of 6%, a volatility
factor of 216% and a fair value of the underlying common shares of $1.53 for
options and restricted stock issued to consultants and the closing market price
on the date of grant for warrants issued to consultants. The expected life
equaled the term of the options, warrants, or restricted shares.
At March 31, 2001 and December 31, 2000, the Company had 450,000 stock
appreciation rights (SAR's) outstanding. These SAR's, issued in 1989, have an
exercise price of $0.30 and can be exercised through November 20, 2001. In
general, each SAR entitles the holder to receive upon exercise an amount equal
to the excess, if any, of the market value per share of Common Stock at the date
of exercise over the exercise price of the SAR, plus any dividends or
distributions per share made by the Company prior to the exercise date. In lieu
of making cash payments, the Company may, and intends to, elect to issue shares
of Common Stock on a one share for one SAR basis. The Company has recorded a
compensation expense in the amount of $232,000 for the three-months March 31,
2001 to reflect the difference between the respective closing market prices of
the Company's Common Stock at March 31, 2001 and December 31, 2000 and the
exercise price of the SAR's.
NOTE H. SUBSEQUENT EVENTS
On May 10, 2001, the Company and AccuMed signed Amendment No. 1 to the
Agreement and Plan of Merger, which extended the termination date of the
agreement until July 31, 2001, unless such date is automatically extended to
September 30, 2001 in accordance with the terms of the amendment. The amendment
also provides that Ampersand will continue to make loans to AccuMed in a
minimum amount of $100,000 and at AccuMed's written request depending on the
business use of funds over the minimum, a maximum amount of $225,000.
8
9
Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
RESULTS OF OPERATIONS
OVERVIEW
See Note B to the Consolidated Financial Statements for background and
historical information on the Company. The Company is primarily engaged in the
design and development of new products to serve the market for cancer screening.
With the exception of the software products and services marketed by the
Company's wholly owned subsidiary, Samba Technologies, Sarl, all other products
have not as yet been introduced to the market for sale.
REVENUES
The Company's revenue for the three-months ended March 31, 2001
amounting to $409,000 was derived entirely from the sale of Samba products and
services, and represents an increase of $47,000, or 13%, over revenues of
$362,000 for the three-months ended March 31, 2000. The average exchange rate
between the U.S. Dollar and the Euro (the currency to which Samba's operating
currency, the French Franc, is fixed) reflects a decline in the value of the
Euro to the U.S. Dollar of approximately 7% from the three-months ending March
31, 2000 to the three-months ending March 31, 2001. This decline in currency
value reduced the translated value of Samba revenue by approximately $28,000 and
therefore reduced the percentage increase in revenue for the quarter by
approximately 50%.
COST AND EXPENSES
COST OF GOODS SOLD
Cost of goods sold for the three-months ended March 31, 2001 amounted
to $278,000 an increase of 46% over the $190,000 reported for the quarter ended
March 31, 2000. The costs for both periods were entirely related to Samba
products and services. The reduction in gross profit on a quarter-to-quarter
comparison reflects a change in the hardware and software/service product mix.
RESEARCH AND DEVELOPMENT EXPENSES
Research and development expenses were $883,000 for the three-months
ended March 31, 2001. These costs represent contracted development and
consulting services, manufacturing design services, contract research, and
in-house development personnel, laboratory expense, clinical trial and other
clinical study costs, and research administration. Research and Development
costs for the three-months ended March 31, 2000 were $806,000. The increase of
$77,000, or 10%, of costs in the 2001 quarter over costs in the 2000 quarter is
attributable to increased laboratory and research personnel and costs related to
clinical trials and other clinical studies offset by a reduction in instrument
development costs and costs related to amortization of option and stock award
valuations. Included in the Research and Development costs are non-cash expenses
of $160,000 and $319,000 for the 2001 and 2000 quarters, respectively, to
reflect the current market value of option grants and restricted stock awards to
non-employee consultants. The options and stock awards are related to services
to be performed over a three-year period and the charge for the respective
quarters reflects the adjusted amortization of their current value over the term
of the contract.
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES
Selling, general and administrative expenses were $1,754,000 for the
three-months ended March 31, 2001, a decrease of $729,000, or 29%, over the
$2,483,000 reported for the three-months ended March 31, 2000. During the first
quarter of 2000, the Company recorded non-cash expenses of $23,000 related to
the amortization of option and warrant valuations and $1,519,000 related to SARs
compared with expenses
9
10
of $207,000 and $232,000, respectively, recorded during the first quarter of
2001, or a combined reduction in expenses related to these items of $1,103,000
on a quarter to quarter basis. Royalty expense for the 2001 quarter was also
reduced by $234,000 as a result of the renegotiation of the AccuMed License
completed during the second quarter of 2000. These expense reductions were
offset by increased sales and marketing costs of $117,000, increased legal and
accounting fees of $355,000 related to litigation, acquisitions, and the
preparation of SEC filings, and other general operating expenses.
OTHER INCOME AND EXPENSE
The Company incurred approximately $227,000 in interest expense during
the three-month period ended March 31, 2001, an increase of $206,000 over the
$21,000 reported for the three-months ended March 31, 2000. The increase
reflects the amortization $180,000 in non-cash debt discount related to the
valuation of warrants issued as additional consideration for notes payable and
the valuation of the beneficial conversion features of two convertible notes
issued in 2000.
NET LOSS
The net loss for the three-months ended March 31, 2001 was $2,703,000,
or $0.09 per share on 30,211,457 weighted average shares outstanding. The net
loss for the three-months ended March 31, 2000 was $3,139,000, or $0.15 per
share on 21,300,522 shares outstanding. The increase in weighted average shares
outstanding primarily reflects the completion of a private equity offering in
April 2000 and the related automatic conversion of outstanding 6% Convertible
Subordinated Notes and accrued interest into Common Stock.
LIQUIDITY AND CAPITAL RESOURCES
The Company's primary cash uses continue to be research, development
and design expenses of the InPath System and related products. The conversion of
those designs through the process of prototypes, manufactured products, clinical
trials, and market introduction requires in-house and contract design work;
medical consultants and advisors; laboratory and research personnel and
facilities, sales and marketing personnel; and administrative and executive
personnel. Operating funds for the business since its inception have been
provided through private offerings of debt and equity in the Company to limited
numbers of U.S. and foreign accredited investors. We may be required to make
additional such offerings in the future in order to continue to support the
operations of the business until some or all of our products are introduced into
the market. At March 31, 2001 the Company had cash on hand of $931,000, an
increase of $918,000 over cash on hand at the previous year-end
In February 2001, the Company completed the private offering of
1,333,856 shares of its Series B Convertible Preferred Stock. The Company
received net cash proceeds from the February 2001 offering of $5,176,000,
including $500,000 received as a deposit in December 2000.
On February 1, 2001 and February 7, 2001, the Company received a
combined $495,000 in cash from Azimuth in exchange for two Promissory notes
bearing interest at 15% per year. On February 20, 2001, the Company repaid
$795,000 to Azimuth covering the principal amounts of the two February notes
plus the principal amounts of two notes issued in December 2000. At the same
time, the Company also paid Azimuth approximately $14, 000 in accrued interest
due on the four notes.
On February 7, 2001, the Company and AccuMed signed a definitive
agreement under which AccuMed would be merged into a wholly owned subsidiary
of the company. Such agreement was amended on May 10, 2001 (See Note H). In
connection with the merger agreement, Ampersand loaned AccuMed $800,000 (which
includes $330,000 of prior loans) when the merger agreement was signed. Under
terms of the merger agreement, Ampersand loaned AccuMed $225,000 on March 1,
2001 and March 30, 2001 and $150,000 on May 1, 2001. Ampersand will continue
making monthly loans to AccuMed, beginning with a June 1, 2001 loan, in amounts
of $100,000. AccuMed may request additional loan amounts each month, above the
$100,000 level, to a maximum of $225,000, based on a written submission to
Ampersand substantiating the business need for the additional loan amount. All
such loans accrue interest at an annual rate equal to the Prime Rate announced
by the LaSalle National Bank, plus 2.5%. All principal and interest due under
all such loans shall be due and payable on the earlier of the termination of
the merger agreement or July 31, 2001, unless such date is automatically
extended to September 30, 2001, in accordance with the terms of the agreement.
All such loans are secured by the grant of a security interest and lien against
the collateral described in a security agreement between the parties.
10
11
The Company used a portion of the proceeds from the sale of its
Series B Convertible Preferred Stock in February 2001 to purchase equipment for
use in clinical trials, make required license payments, reduces past due
balance with vendors and service suppliers, and for general operating purposes.
During the three months ended March 31, 2001 the Company's wholly owned
subsidiary, Samba Technologies, Sarl, reduced borrowings under its revolving
credit line by $49,000.
The Company has incurred significant net losses since its inception.
The Company expects that significant on-going operating expenditures will be
necessary to successfully implement its business plan and develop, manufacture
and market its products. These circumstances raise substantial doubt about the
Company's ability to continue as a going concern. Implementation of the
Company's plans and its ability to continue as a going concern may depend upon
its acquiring additional financing. Management's plans include efforts to obtain
additional capital. The Company has been successful in raising new equity and
reducing debt through the conversion of notes and accrued interest into Common
Stock. However, there can be no assurance that the Company will continue to be
successful in raising additional capital should the need for such capital
arise in the future. If the Company is unable to obtain additional capital, or
generate profitable sales revenues, the Company may be required to curtail the
its product development and other activities and may be forced to cease
operations.
CAUTIONARY STATEMENT FOR PURPOSES OF THE "SAFE HARBOR" PROVISIONS OF THE PRIVATE
SECURITIES LITIGATION REFORM ACT OF 1995.
Certain statements throughout this report are forward looking. These statements
are based on the Company's current expectations and involve many risks and
uncertainties. Some of these risks and uncertainties are factors that affect all
international businesses, while others are specific to the Company and the areas
of the medical products industry in which it operates.
The factors below in some cases have affected and could affect the Company's
actual results, causing results to differ, possibly materially, from those
expressed in this report's forward-looking statements. These factors include:
economic conditions; technological advances in the medical field; demand and
market acceptance risks for new and existing products, technologies, and
healthcare services; the impact of competitive products and pricing;
manufacturing capacity; new plant start-ups; U.S. and international regulatory,
trade, and tax policies; product development risks, including technological
difficulties; ability to enforce patents; and unforeseen foreign regulatory and
commercialization factors.
Currency fluctuations are also a significant variable for global companies,
especially fluctuations in local currencies where hedging opportunities are
unreasonably expensive or unavailable. If the value of the U.S. dollar
strengthens relative to the currencies of the countries in which the Company
markets or intends to market its products, the Company's ability to achieve
projected sales and net earnings in such countries could be adversely affected.
The Company believes that its expectations with regard to forward-looking
statements are based upon reasonable assumptions within the bounds of its
knowledge of its business and operations, but there can be no assurance that the
actual results or performance of the Company will conform to any future results
or performance expressed or implied by such forward-looking statements.
Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The market risk inherent in the Company's financial statements is the potential
loss in fair value arising from adverse changes in interest rates. The Company
does not engage in any hedge transactions or use derivative financial
instruments to reduce its exposure to interest rate changes since all of the
Company's indebtedness is financed at fixed rates. At March 31, 2001, the
carrying amount of the Company's debt instruments approximated their fair value.
In addition, as of March 31, 2001, the Company was not exposed to any material
foreign-currency, commodity-price, equity-price or other type of market or price
11
12
risk. The Company's wholly owned subsidiary, Samba, conducts the majority of its
operations in Europe using EURO and local European currencies. At March 31, 2001
the Company has recorded a negative cumulative translation adjustment of
($84,000) reflecting the current valuation of the Company's investment in and
current account with Samba.
Part II. Other Information
Item 1 Legal Proceedings
None
Item 2 Changes in Securities
In February 2001, the Company sold 1,333,856 shares of its Series B Convertible
Preferred Stock in a private offering to several U.S. and foreign accredited
investors for a total cash sales price of $5,335,424. Several advisory groups
contracted to assist the Company in finding investors for the offering were
compensated through the payment of $159,000 in cash, the issuance of 374,000
shares of Common Stock, and the issuance of warrants to purchase 534,000 shares
of Common Stock at an exercise price of $1.20 per share. Series B Convertible
Preferred Stock was not registered under the Securities Act of 1933, as amended,
in reliance upon the exemption contained in Section 4(2) of the Act.
Item 3 Defaults on Senior Securities
None
Item 4 Submission of Matters to Vote of Security Holders
None
Item 5 Other Information
None
Item 6 Exhibits and Reports on Form 8-K
Exhibits The following exhibits are filed herewith:
Exhibit Number Description
3 Amendment No 1, dated as of May 10,
2001 to the Agreement and Plan of
Merger by and among AccuMed
International, Inc., AccuMed
Acquisition Corp. and Ampersand
Medical Corporation dated as of
February 7, 2001.
Reports on Form 8-K
The Company filed Current Report on Form 8-K dated
February 7, 2001 reporting, under Item 5, the
execution of the Agreement and Plan of Merger by
and among AccuMed International, Inc., AccuMed
Acquisition Corporation, and the Company, dated as
of February 7, 2001.
12
13
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Ampersand Medical Corporation
/s/ Leonard R. Prange
---------------------
Leonard R. Prange
-----------------
President, Chief Operating Officer, Chief
Financial Officer and Secretary
Principal Accounting Officer
Date: May 15, 2000
13